Compare BWBBP & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BWBBP | GNLX |
|---|---|---|
| Founded | N/A | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 110.4M |
| IPO Year | 2018 | 2022 |
| Metric | BWBBP | GNLX |
|---|---|---|
| Price | $19.65 | $2.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $17.25 |
| AVG Volume (30 Days) | 1.7K | ★ 280.4K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.66 | 9.47 |
| EPS | ★ 1.03 | N/A |
| Revenue | N/A | ★ $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.76 | $2.29 |
| 52 Week High | $22.48 | $8.54 |
| Indicator | BWBBP | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 40.28 |
| Support Level | $19.55 | $2.34 |
| Resistance Level | $20.56 | $2.97 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 30.48 | 14.29 |
Bridgewater Bancshares Inc is a financial holding company. Through its subsidiary, it offers various personal and commercial banking products and services such as savings accounts, certificates of deposits, money transfer services, digital wallets, credit and debit cards, safe deposit lockers, different types of loans and advances, commercial deposit accounts, treasury management, and others. The company principally focuses on catering to commercial clients, offering a suite of loan and deposit products. Geographically, it mainly operates in the Twin Cities Metropolitan Statistical Area in the United States.
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.